Skip to main content

Find Clinical Trials

Home
Conditions
Biliary Tract Neoplasms Immunotherapy

Clinical trial condition

Biliary Tract Neoplasms Immunotherapy

Explore clinical trials studying Biliary Tract Neoplasms Immunotherapy. Study availability and eligibility vary by location and protocol.

4 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

Biliary Tract Neoplasms Immunotherapy trial results

Recruiting

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

NCT07704177

Conditions: Biliary Tract Diseases, Biliary Tract Neoplasms, Biliary Tract Neoplasms Immunotherapy, +4 more
Locations: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH) Beijing, Beijing Municipality, China

View Trial Details

Recruiting

A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.

NCT07679399

Conditions: Biliary Tract Diseases, Biliary Tract Neoplasms, Biliary Tract Neoplasms Immunotherapy, +4 more
Locations: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, 100730 Beijing, China

View Trial Details

Recruiting

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

NCT07670273

Conditions: Biliary Tract Diseases, Biliary Tract Neoplasms, Biliary Tract Neoplasms Immunotherapy, +4 more
Locations: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, 100730 Beijing, China

View Trial Details

Recruiting

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

NCT06230471

Conditions: Biliary Tract Neoplasms Immunotherapy
Locations: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH) Beijing, Beijing Municipality, China

View Trial Details